MAO-B

DUBLIN--( BUSINESS WIRE )--The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of Monoamine Oxidase Type-B (MAO-B) Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan. The Monoamine Oxidase Type-B (MAO-B) Inhibitors market report provides insights around existing treatment practices in patients with Monoamine Oxidase Type-B (MAO-B) Inhibitors, approved (if any) and emerging Monoamine Oxidase Type-B (MAO-B) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Monoamine Oxidase Type-B (MAO-B) Inhibitors, along with current and forecasted 7MM Monoamine Oxidase Type-B (MAO-B) Inhibitors market size from 2020-2034 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new Monoamine Oxidase Type-B (MAO-B) Inhibitors in different geographies, along with insights on Monoamine Oxidase Type-B (MAO-B) Inhibitors pricing reimbursements to curate the best opportunities and assess the market's potential. Monoamine Oxidase Type-B (MAO-B) Inhibitors Overview This segment will provide detailed information beginning with the inhibitor journey from discovery of the mutation or protein expression to its entry into clinical development followed by its upcoming commercial potential. This segment will dive into the different indications for which the inhibitor is being developed for, which would further give insights on the potential addressable patient population. Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications. Monoamine Oxidase Type-B (MAO-B) Inhibitors in Clinical Practice This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors. Potential of the emerging Monoamine Oxidase Type-B (MAO-B) Inhibitors in changing the current clinical practice guidelines is crucial to analyze especially when it comes to real world scenario. It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement and non-recommendation in guidelines. Monoamine Oxidase Type-B (MAO-B) Inhibitors Drug Chapters The drug chapter segment of the Monoamine Oxidase Type-B (MAO-B) Inhibitors report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the Monoamine Oxidase Type-B (MAO-B) Inhibitors clinical trial details, pharmacological action, agreements and collaborations related to Monoamine Oxidase Type-B (MAO-B) Inhibitors, their approval timelines, patent details, advantages and disadvantages, latest news and press releases. Monoamine Oxidase Type-B (MAO-B) Inhibitors Marketed Drugs The Monoamine Oxidase Type-B (MAO-B) Inhibitors marketed drug section will provide detailed drug profiles of already approved therapies. Information around clinical development activities, launch timing, regulatory milestones along with safety and efficacy data of the therapy will be included. Monoamine Oxidase Type-B (MAO-B) Inhibitors Emerging Drugs Apart from a comprehensive Monoamine Oxidase Type-B (MAO-B) Inhibitors competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging Monoamine Oxidase Type-B (MAO-B) Inhibitors under the late and mid-stage of clinical development for various indications. Drug Class Insights The Drug Class Insights section will provide comprehensive information on Monoamine Oxidase Type-B (MAO-B) Inhibitors as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of Monoamine Oxidase Type-B (MAO-B) Inhibitors, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs. Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Outlook This section will include details on changing Monoamine Oxidase Type-B (MAO-B) Inhibitors market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space. Monoamine Oxidase Type-B (MAO-B) Inhibitors Drugs Uptake This section focuses on the uptake rate of potential Monoamine Oxidase Type-B (MAO-B) Inhibitors already launched and expected to be launched in the market during 2020-2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. Monoamine Oxidase Type-B (MAO-B) Inhibitors Pipeline Development Activities The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics. Monoamine Oxidase Type-B (MAO-B) Inhibitors Pipeline Development Activities The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Monoamine Oxidase Type-B (MAO-B) Inhibitors. KOL Views To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on Monoamine Oxidase Type-B (MAO-B) Inhibitors' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility. Qualitative Analysis The publisher performs qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape. Market Access and Reimbursement This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy. For more information about this report visit https://www.researchandmarkets.com/r/5igbfk About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN, July 28, 2023 /PRNewswire/ -- The "Parkinson's Disease: Market Insights, Epidemiology, and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. This report presents a detailed analysis of PD, covering its epidemiology, market trends, and emerging treatment options across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Epidemiology Insights: The report provides a comprehensive understanding of PD's epidemiology, including historical and forecasted data on diagnosed prevalent cases, gender-specific cases, age-specific cases, and stage-specific cases in the 7MM. In 2022, the United States had the highest number of diagnosed PD cases, estimated at approximately 1.2 million. The EU4 and the UK collectively reported around 1.2 million diagnosed cases, while Japan accounted for 0.2 million cases. Market Insights: The market size of Parkinson's Disease in 2022 was the largest in the US, reaching approximately USD 1,820 million in the 7MM. In contrast, the United Kingdom had the lowest market size, with USD 135 million. Over the forecast period (2023-2032), the market is expected to witness significant growth due to the introduction of emerging therapies such as Tavapadon, P2B001, BIIB122, ABBV-951, Buntanetap, IPX203, NE3107, CVN424, ITI-214, and CNM-Au8. Current Treatment Scenario and Emerging Therapies: Current treatment options for PD include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists. While these medications manage symptoms, they do not halt disease progression. Promising emerging therapies like Tavapadon, P2B001, BIIB122, ABBV-951, and Buntanetap are expected to revolutionize PD management, offering improved outcomes for patients. Geographical Coverage: The report extensively covers PD insights in the United States, EU4, the UK, and Japan, highlighting regional variations in disease prevalence, treatment practices, and market trends. Parkinson's Disease Market Outlook: The market size of Parkinson's Disease in the 7MM was approximately USD 3,226 million in 2022. It is projected to grow at a CAGR of 11.2% during the forecast period, driven by the increasing diagnosed prevalent cases and the introduction of novel therapies. Pipeline Development Activities: The report offers insights into ongoing clinical trials and emerging therapeutic candidates in Phase III and Phase II, providing a glimpse of the future landscape of PD treatment. Market Access and Reimbursement: A comprehensive assessment of market access and reimbursement policies, cost-effectiveness, and patient assistance programs sheds light on the challenges faced by patients in accessing expensive therapies. KOL Views: Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) in the field of PD provide valuable insights, validating treatment patterns, patient preferences, and challenges in the current treatment landscape. Conclusion: Parkinson's Disease presents a significant healthcare burden globally, necessitating a thorough understanding of its epidemiology and treatment landscape. With emerging therapies on the horizon, the future holds promising advancements in PD management, enhancing patients' quality of life. This report equips stakeholders with critical information to make informed decisions, address unmet needs, and create effective disease management strategies. Through collaborative efforts and innovative treatments, we can strive towards better outcomes for individuals living with Parkinson's Disease and their families. Key Topics Covered: 1. Key Insights 2. Report Introduction 3. Parkinson's disease Market Overview at a Glance 4. Executive Summary of Parkinson's disease 5. Key Events 6. Epidemiology and Market Methodology 7. Disease Background and Overview 8. Epidemiology and Patient Population 9. Patient Journey 10. Marketed Products 11. Emerging Therapies 12. Parkinson's disease: The 7MM Analysis 13. KOL Views 14. SWOT Analysis 15. Unmet Needs 16. Market Access and Reimbursement 17. Acronyms and Abbreviations 18. Appendix A selection of companies mentioned in this report includes: Cerevel Therapeutics Pfizer Pharma Two B AbbVie Biogen Denali Therapeutics Annovis Bio Amneal Pharmaceuticals BioVie Cerevance Clene Nanomedicine Intra-Cellular Therapies Hoffmann-La Roche Prothena Corporation For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Findings to be presented at International Association of Parkinsonism and Related Disorders (IARPD) 2023 World Congress being held May 13-16, 2023. BEDMINSTER, N.J., May 12, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, will share results from a retrospective study evaluating real-world utilization of istradefylline along with other Parkinson's disease (PD) medications among patients with PD.1 These findings will be presented on Sunday, May 14 from 12:15 - 1:15 PM CDT at the International Association of Parkinsonism and Related Disorders (IAPRD) conference in Chicago, Illinois. As PD progresses, approximately 50% of patients will experience off time, which is a return of Parkinson's disease symptoms between doses of levodopa within 5 years of initiating levodopa treatment. 2,3,4NOURIANZ® (istradefylline) is prescription medication indicated as adjunctive treatment to levodopa/carbidopa in adult patients with PD experiencing "off" episodes. Patients with Parkinson's disease are often on multiple medications to manage their PD symptoms or "off" episodes.5 This underscores the need to evaluate polypharmacy medication use in order to contribute to medical understanding of treatment regimens and appropriate patient management. About Study Design This retrospective cohort study investigated the real-world use of istradefylline and other PD-related medications in 734 patients with PD who initiated Nourianz between 9/1/2019-6/30/2020. Patients were identified from the 2019-2020 US Medicare Fee-for-Service (FFS) 100% sample and required to have continuous enrollment during the 6-month pre- and post-index periods, and at least one PD diagnosis in the pre-index period. The study examined the treatment patterns of PD patients six months before and after starting Nourianz, analyzing the usage of levodopa equivalent daily dose (LEDD) and other PD-related medications, such as dopamine (DA) precursors, DA agonists, catechol-o-methyl transferase (COMT) inhibitors, anticholinergic agents, and monoamine oxidase-B (MAO-B) inhibitors. Real-world findings from this retrospective study may not represent the treatment paradigm of all patients with PD. About Parkinson's Disease Parkinson's disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement, and postural instability. Parkinson's disease is caused by a reduction of dopamine levels in certain parts of the brain, such as the substantia nigra and striatum. The loss of dopaminergic neurons in these regions is responsible for the coordination of normal motor function. About Nourianz® (istradefylline) Nourianz® (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes. It is not known if istradefylline is safe and effective in children. Important Safety Information Warnings and Precautions Dyskinesia: istradefylline in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. In clinical trials, 1% of patients treated with either istradefylline 20 mg or 40 mg discontinued treatment because of dyskinesia, compared to 0% for placebo. Hallucinations / Psychotic Behavior: Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with istradefylline. Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking istradefylline. Impulse Control / Compulsive Behaviors: Patients treated with istradefylline and one or more medication(s) for the treatment of Parkinson's disease (including levodopa) may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges. In clinical trials, 1 patient treated with istradefylline 40 mg was reported to have impulse control disorder, compared to no patient on istradefylline 20 mg or placebo. Drug Interactions The maximum recommended dosage in patients taking strong CYP3A4 inhibitors is 20 mg once daily. Avoid use of istradefylline with strong CYP3A4 inducers. Specific Populations Pregnancy: Based on animal data, may cause fetal harm. Hepatic impairment: The maximum recommended dosage of istradefylline in patients with moderate hepatic impairment is 20 mg once daily. Avoid use in patients with severe hepatic impairment. Adverse Reactions The most common adverse reactions with an incidence ≥5% and occurring more frequently than with placebo were dyskinesia (15%, 17%, and 8%), dizziness (3%, 6%, and 4%), constipation (5%, 6%, and 3%), nausea (4%, 6%, and 5%), hallucination (2%, 6%, and 3%), and insomnia (1%, 6%, and 4%) for istradefylline 20 mg, 40 mg, and placebo, respectively. You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or . Please click to see full Prescribing Information for Nourianz. About Kyowa Kirin Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a more than 70-year heritage, the company applies cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients across multiple therapeutic areas such as nephrology, oncology, immunology/allergy, and neurology. Across its four regions – Japan, Asia Pacific, North America and EMEA/International – Kyowa Kirin focuses on its purpose, to make people smile, and is united by its shared values of commitment to life, teamwork, innovation, and integrity. You can learn more about the Kyowa Kirin North America at: . Nourianz® is a trademark of Kyowa Kirin Co., Ltd. REFERENCES Rezak, M., Qian, J., Zhao, Y., et al. (2023). Real-World Utilization of Istradefylline Among Patients with Parkinson's Disease. Data presented at the 2023 World Congress on Parkinson's Disease and Related Disorders, May 13-16, 2023, Chicago, IL. Hickey, P., & Stacy, M. (2011). Available and Emerging Treatments for Parkinson's Disease: A Review. Drug Design, Development and Therapy, 5, 241-254. doi:10.2147/DDDT.S11836 Stacy, M., Bowron, A., Guttman, M., et al. (2005). Identification of Motor and Nonmotor Wearing-Off in Parkinson's Disease: Comparison of a Patient Questionnaire Versus a Clinician Assessment. Movement Disorders, 20(6), 726-733. doi:10.1002/mds.20383 Chou, K. L., Stacy, M., Simuni, T., et al. (2018). The Spectrum of "Off" in Parkinson's Disease: What Have We Learned Over 40 Years? Parkinsonism & Related Disorders, 51, 9-16. doi:10.1016/j.parkreldis.2018.02.001 Tan, Q. Y., Zhang, Z. C., Zhang, Y., et al. (2021). The Experiences of Treatment Burden in People with Parkinson's Disease and Their Caregivers: A Systematic Review of Qualitative Studies. Journal of Parkinson's Disease, 11(4), 1597-1617. doi:10.3233/JPD-202604. SOURCE Kyowa Kirin